FindTrial
Sign In

To check for the markers in blood in patients with pemphigus vulgaris.

Estimation of salivary and serum IgG and IgA anti desmoglein antibody levels in pemphigus vulgaris patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/12/010871
Enrollment
30
Registered
2017-12-13
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Pemphigus vulgaris

Interventions

Control Intervention1: not applicable: not applicable Control Intervention2: NIL: NIL

Sponsors

IADVL Research grant
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Consented newly diagnosed pemphigus vulgaris patients of all age group and sex Consented relapsed pemphigus vulgaris patients of all ages and sex Healthy first degree relatives of diagnosed pemphigus vulgaris patients

Exclusion criteria

Exclusion criteria: Non consented patients Patients in remission

Design outcomes

Primary

MeasureTime frame
Salivary anti desmoglien levels corelate with that of serum anti desmoglien levels and also disease severity in patients With pemphigus vulgaris Timepoint: 3 Months—

Secondary

MeasureTime frame
Salivary anti desmoglien level estimation can be used as a non invasive alternative in predicting the course and severity Pemphigus Vulgaris. Timepoint: 3months—

Countries

India

Contacts

Public ContactDr Vinutha Rangappa

JSS Medical college

drvinutharangappa@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026